135 related articles for article (PubMed ID: 31006665)
1. Methylation of tumour suppressor genes associated with thyroid cancer.
Botezatu A; Iancu IV; Plesa A; Manda D; Popa O; Bostan M; Mihaila M; Albulescu A; Fudulu A; Vladoiu SV; Huica I; Dobrescu R; Anton G; Badiu C
Cancer Biomark; 2019; 25(1):53-65. PubMed ID: 31006665
[TBL] [Abstract][Full Text] [Related]
2. Alterations of regulatory factors and DNA methylation pattern in thyroid cancer.
Iancu IV; Botezatu A; Plesa A; Huica I; Fudulu A; Albulescu A; Bostan M; Mihaila M; Grancea C; Manda DA; Dobrescu R; Vladoiu SV; Anton G; Badiu CV
Cancer Biomark; 2020; 28(2):255-268. PubMed ID: 32390600
[TBL] [Abstract][Full Text] [Related]
3. Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling.
Lindsey JC; Lusher ME; Anderton JA; Bailey S; Gilbertson RJ; Pearson AD; Ellison DW; Clifford SC
Carcinogenesis; 2004 May; 25(5):661-8. PubMed ID: 14688019
[TBL] [Abstract][Full Text] [Related]
4. DKK3 is a potential tumor suppressor gene in papillary thyroid carcinoma.
Yin DT; Wu W; Li M; Wang QE; Li H; Wang Y; Tang Y; Xing M
Endocr Relat Cancer; 2013 Aug; 20(4):507-14. PubMed ID: 23702469
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic signatures of familial cancer are characteristic of tumor type and family category.
Joensuu EI; Abdel-Rahman WM; Ollikainen M; Ruosaari S; Knuutila S; Peltomäki P
Cancer Res; 2008 Jun; 68(12):4597-605. PubMed ID: 18559504
[TBL] [Abstract][Full Text] [Related]
6. Hypermethylation of RUNX3 but not WIF1 gene and its association with stage and nodal status of tongue cancers.
Supic G; Kozomara R; Jovic N; Zeljic K; Magic Z
Oral Dis; 2011 Nov; 17(8):794-800. PubMed ID: 21819494
[TBL] [Abstract][Full Text] [Related]
7. Silencing of the maspin gene by promoter hypermethylation in thyroid cancer.
Boltze C; Schneider-Stock R; Quednow C; Hinze R; Mawrin C; Hribaschek A; Roessner A; Hoang-Vu C
Int J Mol Med; 2003 Oct; 12(4):479-84. PubMed ID: 12964023
[TBL] [Abstract][Full Text] [Related]
8. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer.
Hu S; Liu D; Tufano RP; Carson KA; Rosenbaum E; Cohen Y; Holt EH; Kiseljak-Vassiliades K; Rhoden KJ; Tolaney S; Condouris S; Tallini G; Westra WH; Umbricht CB; Zeiger MA; Califano JA; Vasko V; Xing M
Int J Cancer; 2006 Nov; 119(10):2322-9. PubMed ID: 16858683
[TBL] [Abstract][Full Text] [Related]
9. Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A non-invasive tool panel for early detection of thyroid cancer.
Zane M; Agostini M; Enzo MV; Casal Ide E; Del Bianco P; Torresan F; Merante Boschin I; Pennelli G; Saccani A; Rubello D; Nitti D; Pelizzo MR
Biomed Pharmacother; 2013 Oct; 67(8):723-30. PubMed ID: 23931930
[TBL] [Abstract][Full Text] [Related]
10. [Aberrant methylation of hMLH1 gene promoter in papillary thyroid cancer and its clinical significance].
Lu XX; Ge MH; Ling ZQ; Hu SS; Xu J; Zheng CM; Tan Z; Chen C
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):833-6. PubMed ID: 24447481
[TBL] [Abstract][Full Text] [Related]
11. Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer.
Guan H; Ji M; Hou P; Liu Z; Wang C; Shan Z; Teng W; Xing M
Cancer; 2008 Jul; 113(2):247-55. PubMed ID: 18470905
[TBL] [Abstract][Full Text] [Related]
12. Correlation between BRAF mutation and promoter methylation of TIMP3, RARβ2 and RASSF1A in thyroid cancer.
Brait M; Loyo M; Rosenbaum E; Ostrow KL; Markova A; Papagerakis S; Zahurak M; Goodman SM; Zeiger M; Sidransky D; Umbricht CB; Hoque MO
Epigenetics; 2012 Jul; 7(7):710-9. PubMed ID: 22694820
[TBL] [Abstract][Full Text] [Related]
13. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.
Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T
JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773
[TBL] [Abstract][Full Text] [Related]
14. Aberrant methylation as a main mechanism of TSGs silencing in PTC.
Czarnecka K; Pastuszak-Lewandoska D; Migdalska-Sek M; Nawrot E; Brzezinski J; Dedecjus M; Pomorski L; Brzezianska E
Front Biosci (Elite Ed); 2011 Jan; 3(1):137-57. PubMed ID: 21196293
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional regulation of the potential tumor suppressor ABI3 gene in thyroid carcinomas: interplay between methylation and NKX2-1 availability.
Moraes L; Galrão AL; Rubió I; Cerutti JM
Oncotarget; 2016 May; 7(18):25960-70. PubMed ID: 27036019
[TBL] [Abstract][Full Text] [Related]
16. [Methylation and expression of RUNX3 gene promoter in papillary thyroid carcinoma].
Yin DT; Cao SL; Wang YF; Li HQ; Zhou YB; Zheng LY; Jiang JH; Wang QD
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 May; 46(5):417-9. PubMed ID: 21781566
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival.
Mancikova V; Buj R; Castelblanco E; Inglada-Pérez L; Diez A; de Cubas AA; Curras-Freixes M; Maravall FX; Mauricio D; Matias-Guiu X; Puig-Domingo M; Capel I; Bella MR; Lerma E; Castella E; Reverter JL; Peinado MÁ; Jorda M; Robledo M
Int J Cancer; 2014 Aug; 135(3):598-610. PubMed ID: 24382797
[TBL] [Abstract][Full Text] [Related]
18. Specific reversal of tumor-suppressor gene promoter hypermethylation with bovine oocyte extract.
Wang Z; Gao H; Wang H; Ren X; Bao L; Sa R; Wang J; Bai H; Yu H
Oncol Rep; 2013 Jul; 30(1):179-84. PubMed ID: 23670097
[TBL] [Abstract][Full Text] [Related]
19. Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma.
Kunstman JW; Korah R; Healy JM; Prasad M; Carling T
Surgery; 2013 Dec; 154(6):1255-61; discussion 1261-2. PubMed ID: 24383114
[TBL] [Abstract][Full Text] [Related]
20. Silencing of tumor suppressor genes RASSF1A, SLIT2, and WIF1 by promoter hypermethylation in hereditary breast cancer.
Alvarez C; Tapia T; Cornejo V; Fernandez W; Muñoz A; Camus M; Alvarez M; Devoto L; Carvallo P
Mol Carcinog; 2013 Jun; 52(6):475-87. PubMed ID: 22315090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
